Synopsis
Synopsis
0
VMF
0
FDF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Evista
2. Keoxifene
3. Keoxifene Hydrochloride
4. Ly 139481
5. Ly 156758
6. Ly-139481
7. Ly-156758
8. Ly139481
9. Ly156758
10. Raloxifene
11. Raloxifene Hcl
1. 82640-04-8
2. Raloxifene Hcl
3. Evista
4. Keoxifene Hydrochloride
5. Keoxifene
6. Optruma
7. Raloxifene Teva
8. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride
9. Raloxifene (hydrochloride)
10. Ly 156758
11. Ly156758
12. Ly-156758
13. Nsc-706725
14. 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol Hydrochloride
15. Chebi:50740
16. Evista (raloxifene Hydrochloride)
17. 4f86w47br6
18. 6-hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride
19. Dsstox_cid_14181
20. Dsstox_rid_79119
21. Dsstox_gsid_34181
22. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
23. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride
24. Smr000058508
25. Raloxifene Hydrochloride [usan]
26. Ncgc00015889-05
27. Cas-82640-04-8
28. C28h27no4s.hcl
29. Loxifen
30. Unii-4f86w47br6
31. Sr-01000076102
32. Cdt-raloxifene
33. Raloxifene-d4 Hcl
34. Raloxifene Cloridrato
35. Evista (tn)
36. Mfcd01938233
37. Prestwick_1035
38. Raloxifene Hydrochloride [usan:usp]
39. Methanone, Hydrochloride
40. Cloridrato De Raloxifeno
41. Clorhidrato De Raloxifeno
42. Chlorhydrate De Raloxifene
43. Ly139481 Hydrochloride
44. Ly156758 Hydrochloride
45. Chembl1116
46. Schembl19077
47. Mls000859902
48. Mls001332533
49. Mls001332534
50. Mls002222293
51. Raloxifene Hydrochloride, Solid
52. Evista, Raloxifene Hydrochloride
53. Raloxifene Hydrochloride- Bio-x
54. Dtxsid1034181
55. Ly156758 (keoxifene) Hcl
56. Ly-139481 Hcl
57. Hms1570n05
58. Pharmakon1600-01505622
59. Amy23426
60. Bcp05713
61. Raloxifene Hydrochloride (jan/usp)
62. Tox21_110255
63. Tox21_302369
64. Tox21_501051
65. Hy-13738a
66. Nsc706725
67. Nsc759285
68. Raloxifene Hydrochloride [mi]
69. S1227
70. Raloxifene Hydrochloride [jan]
71. Akos008131940
72. Tox21_110255_1
73. Ac-8390
74. Ccg-213497
75. Cs-1775
76. Ds-2162
77. Ks-1102
78. Lp01051
79. Nc00665
80. Nsc 706725
81. Nsc 759285
82. Nsc-759285
83. Raloxifene Hydrochloride [mart.]
84. Raloxifene Hydrochloride [vandf]
85. Ncgc00015889-03
86. Ncgc00015889-11
87. Ncgc00092353-01
88. Ncgc00092353-03
89. Ncgc00094334-01
90. Ncgc00094334-02
91. Ncgc00255153-01
92. Ncgc00261736-01
93. Raloxifene Hydrochloride [usp-rs]
94. Raloxifene Hydrochloride [who-dd]
95. Br164310
96. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride
97. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride (1:1)
98. Raloxifene Hydrochloride [ema Epar]
99. Eu-0101051
100. Ft-0630912
101. R0109
102. Sw197106-5
103. En300-52517
104. Raloxifene Hydrochloride [orange Book]
105. D02217
106. R 1402
107. Raloxifene Hydrochloride [ep Monograph]
108. Raloxifene Hydrochloride [usp Impurity]
109. Raloxifene Hydrochloride [usp Monograph]
110. 640r048
111. A840401
112. Q-201656
113. Sr-01000076102-2
114. Sr-01000076102-9
115. Q27122215
116. (6-oxo-1,6-dihydro-pyridazin-3-yloxy)-aceticacid
117. Raloxifene Hydrochloride, European Pharmacopoeia (ep) Reference Standard
118. Raloxifene Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
119. Raloxifene Hydrochloride, United States Pharmacopeia (usp) Reference Standard
120. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride
121. (6-oh-2-(4-oh-ph)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)ph)methanone Hydrochloride
122. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone Hydrochloride
123. [6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride
124. [6-hydroxy-2-(4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride
125. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride
126. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone, Monohydrochloride
127. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
128. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
129. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
130. [6-hydroxy-2[4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
131. 1-[2-(4-{[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]carbonyl}phenoxy)ethyl]piperidinium Chloride
132. 6-hydroxy-2-(4-hydroxyphenyl)-3-[ 4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, Hydrochloride
133. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]-thiophene Hydrochloride
134. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene Hydrochloride
135. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Methanone Hydrochloride
136. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Ketone Hydrochloride
137. 6-hydroxy-2-(p-hydroxyphenyl)benzo(.beta.)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride
138. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(.beta.)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride
139. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, Hydrochloride (1:1)
140. Raloxifene Hydrochloride For Peak Identification, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 510.0 g/mol |
---|---|
Molecular Formula | C28H28ClNO4S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 7 |
Exact Mass | 509.1427572 g/mol |
Monoisotopic Mass | 509.1427572 g/mol |
Topological Polar Surface Area | 98.2 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 655 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Evista |
PubMed Health | Raloxifene (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Lilly |
2 of 4 | |
---|---|
Drug Name | Raloxifene hydrochloride |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Tentative Approval; Prescription |
Company | Teva Pharms Usa; Invagen Pharms; Watson Labs |
3 of 4 | |
---|---|
Drug Name | Evista |
PubMed Health | Raloxifene (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Lilly |
4 of 4 | |
---|---|
Drug Name | Raloxifene hydrochloride |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Tentative Approval; Prescription |
Company | Teva Pharms Usa; Invagen Pharms; Watson Labs |
Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5. 1).
Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.
When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Selective Estrogen Receptor Modulators
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Estrogen Antagonists
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)
G03XC01
G03XC01
G03XC01
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2015-01-21
Application Number : 200825
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2016-04-08
Application Number : 208206
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2015-08-28
Application Number : 204310
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code : AB
Brand Name : EVISTA
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 1997-12-09
Application Number : 20815
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD :
TE Code :
Brand Name : EVISTA
Dosage Form : TABLET; ORAL
Dosage Strength : 60MG
Approval Date :
Application Number : 22042
RX/OTC/DISCN :
RLD :
TE Code :
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2016-03-22
Application Number : 204491
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2014-09-24
Application Number : 90842
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2016-10-12
Application Number : 206384
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2014-03-04
Application Number : 78193
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RALOXIFENE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date : 2020-08-18
Application Number : 211324
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Regulatory Info :
Registration Country : Sweden
Brand Name : Optruma
Dosage Form : FILMDRAGERAD TABLETT
Dosage Strength : 60 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : OPTRUMA
Dosage Form : Film-Coated Tablets
Dosage Strength : 60 mg
Packaging : 28 UNITS 60 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Raloxifene
Dosage Form : Raloxifene 60Mg 28 Combined Oral Use
Dosage Strength : 28 cpr riv 60 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : RALOXIFENE SANDAZ
Dosage Form : Film-Coated Tablets
Dosage Strength : 60 mg
Packaging : 28 UNITS 60 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Brand Name : Raloxifene STADA
Dosage Form : FILM COATED PILL
Dosage Strength : 60 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Spain
Brand Name : Raloxifene Mylan Pharmaceuticals 60Mg 28 Pills Recub Efg
Dosage Form : Tablet
Dosage Strength : 60 Mg/Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : Raloxifene Kern Pharma 60Mg 28 Coated Tablets Efg
Dosage Form : Coated Tablet
Dosage Strength : 60 Mg/Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : 28 Tecnigen Raloxifene 60Mg Film-Coated Tablets Efg
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : Raloxifene Teva 60Mg 28 Tablets Coated Film Efg
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : 28 Vir Raloxifene 60Mg Film-Coated Tablets Efg
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Canada
Brand Name : APO-RALOXIFENE
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging : 100
Approval Date :
Application Number : 2279215
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : EVISTA
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging : 28
Approval Date :
Application Number : 2239028
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : JAMP RALOXIFENE
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number : 2540681
Regulatory Info :
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PMS-RALOXIFENE
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging : 30/100
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : ACT RALOXIFENE
Dosage Form : TABLET
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number : 2358840
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Australia
Brand Name : Fixta 60
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Fixta 60
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : RALOVISTA
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : RALOVISTA
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Evista
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Evista
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Raloxifene GH
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Raloxifene GH
Dosage Form : tablet
Dosage Strength : 60 mg
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company :
Raloxifene HCl
Drug Cost (USD) : 1,321,400
Year : 2022
Prescribers : 733
Prescriptions : 3164
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Raloxifene HCl
Drug Cost (USD) : 71,906,194
Year : 2022
Prescribers : 174407
Prescriptions : 744969
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Raloxifene HCl
Drug Cost (USD) : 1,622,729
Year : 2021
Prescribers : 901
Prescriptions : 3884
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Raloxifene HCl
Drug Cost (USD) : 78,803,659
Year : 2021
Prescribers : 186283
Prescriptions : 808653
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Raloxifene HCl
Drug Cost (USD) : 97,532,753
Year : 2020
Prescribers : 196048
Prescriptions : 895686
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Raloxifene HCl
Drug Cost (USD) : 1,994,285
Year : 2020
Prescribers : 1111
Prescriptions : 5016
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Raloxifene HCl
Drug Cost (USD) : 2,307,340
Year : 2019
Prescribers : 1334
Prescriptions : 6074
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Raloxifene HCl
Drug Cost (USD) : 126,231,705
Year : 2019
Prescribers : 212801
Prescriptions : 991707
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Raloxifene HCl
Drug Cost (USD) : 2,726,906
Year : 2018
Prescribers : 1679
Prescriptions : 7501
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Raloxifene HCl
Drug Cost (USD) : 152,387,582
Year : 2018
Prescribers : 227176
Prescriptions : 1093282
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 60 mg
Price Per Pack (Euro) : 86.262
Published in :
Country : Norway
RX/OTC/DISCN :
Daiichi Sankyo Europe GmbH
Dosage Form : Antic-calc Tablet
Dosage Strength : 60 mg
Price Per Pack (Euro) : 31.867
Published in :
Country : Norway
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Daiichi Sankyo Europe GmbH
Dosage Form : Antic-calc Tablet
Dosage Strength : 60 mg
Price Per Pack (Euro) : 86.262
Published in :
Country : Norway
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Farm Agon
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 60 mg
Price Per Pack (Euro) : 86.262
Published in :
Country : Norway
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Coated Tablet
Dosage Strength : 60 Mg/Coated Tablet
Price Per Pack (Euro) : 20.64
Published in :
Country : Spain
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Coated Tablet
Dosage Strength : 60 Mg/Coated Tablet
Price Per Pack (Euro) : 20.64
Published in :
Country : Spain
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Price Per Pack (Euro) : 20.64
Published in :
Country : Spain
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Price Per Pack (Euro) : 20.64
Published in :
Country : Spain
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Price Per Pack (Euro) : 20.64
Published in :
Country : Spain
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Film Coated Tablet
Dosage Strength : 60 Mg/Film Coated Tablet
Price Per Pack (Euro) : 20.64
Published in :
Country : Spain
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Raloxifene Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Raloxifene Hydrochloride, including repackagers and relabelers. The FDA regulates Raloxifene Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Raloxifene Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Raloxifene Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Raloxifene Hydrochloride supplier is an individual or a company that provides Raloxifene Hydrochloride active pharmaceutical ingredient (API) or Raloxifene Hydrochloride finished formulations upon request. The Raloxifene Hydrochloride suppliers may include Raloxifene Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Raloxifene Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Raloxifene Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Raloxifene Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Raloxifene Hydrochloride DMFs exist exist since differing nations have different regulations, such as Raloxifene Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Raloxifene Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Raloxifene Hydrochloride USDMF includes data on Raloxifene Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Raloxifene Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Raloxifene Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Raloxifene Hydrochloride Drug Master File in Japan (Raloxifene Hydrochloride JDMF) empowers Raloxifene Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Raloxifene Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Raloxifene Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Raloxifene Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Raloxifene Hydrochloride Drug Master File in Korea (Raloxifene Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Raloxifene Hydrochloride. The MFDS reviews the Raloxifene Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Raloxifene Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Raloxifene Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Raloxifene Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Raloxifene Hydrochloride suppliers with KDMF on PharmaCompass.
A Raloxifene Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Raloxifene Hydrochloride Certificate of Suitability (COS). The purpose of a Raloxifene Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Raloxifene Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Raloxifene Hydrochloride to their clients by showing that a Raloxifene Hydrochloride CEP has been issued for it. The manufacturer submits a Raloxifene Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Raloxifene Hydrochloride CEP holder for the record. Additionally, the data presented in the Raloxifene Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Raloxifene Hydrochloride DMF.
A Raloxifene Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Raloxifene Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Raloxifene Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Raloxifene Hydrochloride written confirmation (Raloxifene Hydrochloride WC) is an official document issued by a regulatory agency to a Raloxifene Hydrochloride manufacturer, verifying that the manufacturing facility of a Raloxifene Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Raloxifene Hydrochloride APIs or Raloxifene Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Raloxifene Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Raloxifene Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Raloxifene Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Raloxifene Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Raloxifene Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Raloxifene Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Raloxifene Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Raloxifene Hydrochloride suppliers with NDC on PharmaCompass.
Raloxifene Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Raloxifene Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Raloxifene Hydrochloride GMP manufacturer or Raloxifene Hydrochloride GMP API supplier for your needs.
A Raloxifene Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Raloxifene Hydrochloride's compliance with Raloxifene Hydrochloride specifications and serves as a tool for batch-level quality control.
Raloxifene Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Raloxifene Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Raloxifene Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Raloxifene Hydrochloride EP), Raloxifene Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Raloxifene Hydrochloride USP).
LOOKING FOR A SUPPLIER?